novo nordisk tirzepatide FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by and Eli Lilly Novo Nordisk's Market Value Sheds

Given the immense popularity of GLP-1 receptor agonists for weight loss and diabetes management, semaglutide could soon be recognized not just as a metabolic therapy but as a potential neuroprotective agent , offering hope for millions at risk of Alzheimers

Both semaglutide and liraglutide injections showed improvements not only in diabetes control (they reduce the A1C test, a marker for blood sugar, by 1 to 1.5 percentage points), but in death due to heart disease and in death due to any cause, compared to a placebo treatment

Bioidentical pellets are rice-sized hormone implants placed under the skin (usually hip or buttock) during a quick in-office procedure

In rodent animal models, GLP-1RAs increased thyroid paracellular cell (C-cell) proliferation and the incidence of tumors

The program took effect July 1, 2026 and runs through December 31, 2027